Laurus Labs FCF Conversion
The FCF Conversion Rate (FCF/EBITDA) of Laurus Labs (LAURUSLABS.NS) as of Aug 1, 2026 is -10.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was -7.86 % — a change of 39.71% (lower).
Get this data via API
Financial Data API
FCF Conversion
-10.98 %
YoY
39.71%
Last updated:
FCF Conversion Rate (FCF/EBITDA) of Laurus Labs is 2026 -10.98 % . FCF Conversion Rate (FCF/EBITDA) of Laurus Labs was 2025 -7.86 % . It decreases by 39.71% lower compared to the previous year.
Access this data via the Eulerpool API
Laurus Labs Stock analysis
What does Laurus Labs do? Laurus Labs Ltd is an Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients for generics and innovative drugs. Since its establishment in 2005, the company has become one of the leading providers of API products on the global market.
Answer: Laurus Labs Ltd is an Indian pharmaceutical company specializing in the production of active pharmaceutical ingredients for generics and innovative drugs. Laurus Labs is one of the most popular companies on Eulerpool.
Frequently Asked Questions about Laurus Labs stock
FCF Conversion Rate (FCF/EBITDA) of Laurus Labs is -10.98 % in 2026.
Access this data via the Eulerpool API
Cash Flow — Laurus Labs
Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A
All Key Metrics — Laurus Labs
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth